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Vivax malaria is deservedly receiving more attention than in the
past (Baird, 2007; Price et al., 2007). However, research into the
causative agent of relapsing malaria, Plasmodium vivax, lags
considerably behind that of Plasmodium falciparum. Aside from a
general lack of funding, a key reason for the research effort dispar-
ity between these two important malaria parasite species is that a
robust continuous culture method for P. falciparum was developed
in the late 1970s, whereas the continuous culture of P. vivax eryth-
rocytic stages still eludes us to this day (Galinski and Barnwell,
2008; Mueller et al., 2009; Baird, 2012).
Many funding bodies and vivax research teams correctly
identify ‘the development of a continuous culture methodology
of P. vivax’ as a central challenge facing the malaria research com-
munity. Unfortunately, the realisation of this goal in the short to
medium term remains remote. This failure seems to have a morale
sapping effect on P. vivax research, whereby groups that would
ordinarily be interested in vivax malaria will continue to focusInc. Published by Elsevier Ltd. Op
unology Network, Biopolis,
re (B. Russell). Tel.: +65 6407
ll), renia_laurent@immunol.on P. falciparum until someone ﬁnally ‘‘cracks’’ the solution to P. vi-
vax continuous culture. This ‘sitting on our hands’ attitude towards
meaningful P. vivax research is not helped by the apparent view of
some reviewers and editors of leading journals that ‘if you can’t
transfect it, you’re not doing real science’!
Clearly the plethora of gene complementation studies seen in P.
falciparum, which essentially rely on continuous culture, have been
valuable. However, it is equally true that almost all of the
fundamental discoveries that shape the way we view and under-
stand malaria (and have had a signiﬁcant impact on the control
and treatment of malaria globally) were discovered prior to stable
transfection of P. falciparum. One can also question the validity of
many ﬁndings using strains and clones of Plasmodium spp. that have
spent decades in in vitro culture (or passage though simianmodels)
outside the rigors of selective pressures imposed by their human
and anopheline hosts. Even if wewere able to develop a P. vivax con-
tinuous culture method tomorrow, would continuous culture of P.
vivax really provide the panacea that most researchers predict it
to be? Perhaps, we should instead focus on the questions we need
to answer now and ask if the available methods and tools might
sufﬁce to do so? The aim of this review is to highlight the tools
and methods that are currently applied to successfully study fresh
and thawed human isolates of P. vivax. After a brief introduction
to the central methodology of ex vivo studies on the
P. vivax erythrocytic stages and its prerequisites (Fig. 1), thisen access under CC BY-NC-ND license. 
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sitivity testing, invasion assays, pathobiology and advanced molec-
ular investigations. The protocols will not be discussed in detail,
because the intention of this review is to provide a clear index of
achievable options for laboratories considering the study of P. vivax.
Furthermore, it is important to note that this commentary will not
address primate-based (in vivo or ex vivo) (Stewart, 2003) or mos-
quito transmission studies, two important contributors to vivax
malaria research that are, however, out of the reach of most labora-
tories because they require expensive biosecurity facilities and
highly specialised staff (e.g. veterinarians certiﬁed to care for
non-human primates). The human ex vivo work that is covered in
this review is accessible to any laboratory with basic equipment
(a centrifuge, an incubator and a candle jar). The protocols are
low cost and laboratory technicians can be (and have been)
successfully trained to conduct every method discussed below
within 1 week.2. General overview of the central methodology ex vivo
2.1. Challenges facing clinical investigators
Before starting on the speciﬁcs of ex vivo studies, it is essential
to understand that all of the methods rely on the ethical collection
of infected human blood, usually from patients living in vivax ma-
laria endemic regions. Although this would seem self-evident to
many, there are important political and practical considerations
in the collection of P. vivax-infected blood, and these will ulti-
mately decide the success of any vivax research plan. First, theFig. 1. The central strategy for the ex vivo processing of Plasmestablishment of strong long-term links with clinical partners
and research teams working in an endemic region is crucial (Baird,
2012). Far too often, researchers in sophisticated laboratories in
prestigious institutions see P. vivax and other human parasite iso-
lates as consumable products and consequently treat the collecting
clinics like ‘convenience stores’, sometimes relegating their ﬁeld
counterparts to the footnotes and the acknowledgments. It is
important to be cognizant of the fact that signiﬁcant material
and intellectual challenges are involved in the collection of P. vivax
isolates by venipuncture. Collection of any Plasmodium spp. iso-
lates is only possible after the following requirements are met: ex-
tended community consultation, detailed ethical review, clinical
diagnosis and support (ensuring that adequately trained doctors,
nurses, laboratory technicians and microscopes are located at the
point of care), patient consent (especially when dealing with cul-
tural barriers associated with blood collection), and logistics that
will ensure that the fresh isolates reach the processing laboratory
within 6 h of collection. The position and provision of a ﬁeld labo-
ratory is a major exercise trade-off, as it must be close to the
clinic(s) where samples are being collected, but close enough to
transport nodes and public utilities (water supply and reasonably
stable electrical supply if liquid nitrogen is not available). While
it is possible to conduct studies with limited objectives using P. vi-
vax isolates, requiring nothing more than material transfer agree-
ment and an informal mutual understanding, more often than
not, what at ﬁrst seems a small project often leads to more ex-
tended studies involving numerous sample collections, where it
becomes important to consider longer term agreements involving
local capacity in building and conducting experiments in the actual
ﬁeld site and laboratory.odium vivax isolates and for the downstream applications.
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Aside from the number of P. vivax samples needed for collec-
tion, it is important to communicate detailed inclusion criteria to
the ﬁeld team. These criteria include the minimum parasitaemia
(usually >1/1,000 red blood cells (RBCs)) and the parasite stage re-
quired (e.g. >80% ring forms). For most studies it is best to exclude
mixed species infections as well as patients who have been treated
with an antimalarial drug (such as chloroquine) or an antibiotic
drug (such as doxycycline) within the previous 3 weeks. It is
important to carefully estimate how much blood is to be collected
and what sort of anticoagulant used (5 ml of whole blood collected
into a heparin or a citrate tube, are usually more than enough). It is
necessary to avoid using EDTA as an anticoagulant because it re-
duces parasite viability and affects the biomechanical properties
of RBCs (Weed et al., 1969). The reported inhibitory effects of hep-
arin (Lam et al., 2004) are unlikely to affect downstream PCR appli-
cations given that the numerous processing steps will almost
completely remove all traces of heparin from the infected RBC
(IRBC) fraction. A Giemsa stained thick and thin ﬁlm slide must
be taken at the time of collection for storage and future reference.
Plasmodium vivax samples should be kept in the dark at room tem-
perature (15–28 C) prior to processing.2.3. Early processing steps
The rapid and efﬁcient processing of P. vivax isolates at this crit-
ical stage will determine the success of all of the downstream
experiments. All fresh isolates should be processed as soon as pos-
sible after collection; 6 h being the maximum time permitted. After
removal and freezing of the plasma, it is important to decide
whether subsequent work requires leukocyte removal. In our expe-
rience, apart from paired comparison of ex vivo and clinical re-
sponses, almost all applications require the complete removal of
leukocytes and platelets. The presence of leukocytes in ex vivo as-
says reduces the overall parasitaemia in culture through phagocy-
tosis, which confounds sensitivity assays by reducing antimalarial
drug availability. Moreover, these human cells are a source of
unacceptable contamination in P. vivax genomic studies
(Kaewpongsri et al., 2011). The degree to which the isolate needs
to be depleted of leukocytes depends on the application and these
will be discussed in the following sections.
Of the methods available to remove leukocytes, perhaps the
most cost effective is cellulose ﬁltration (Sriprawat et al., 2009).
The most commonly used form of cellulose powder is CF11. Unfor-
tunately the main supplier, Whatman™, has recently discontinued
the production of this valuable reagent. However, recent unpub-
lished trials suggest that any medium-sized cellulose ﬁbre powder
(e.g. Sigma Catalogue No. C6288) has identical leukocyte retention
properties. Another alternative to CF11 is a promising non-woven
fabric ﬁlter recently developed in China (Tao et al., 2011); however
these commercial ﬁlters are still signiﬁcantly more expensive than
cellulose ﬁltration and are currently difﬁcult to order. After leuko-
cyte depletion, it is important to make post-ﬁltration thick and thin
ﬁlms, from which accurate parasitaemia and parasite staging can
be obtained, because optimal use of any given isolate is largely
dependent on the P. vivax stage and parasitaemia. High parasitae-
mias (>0.5%) and a high proportion of early stages (>80% ring
stages) provide the researcher with the best possible circum-
stances that would allow this isolate to be used for any combina-
tion of the applications highlighted in this review. Fewer
different investigations are possible with lower parasitaemia or
with a high proportion of late stage parasites, although the latter
are particularly useful for invasion assays or to enhance DNA
yields.2.4. Cryopreservation of P. vivax
If the isolate collected is predominantly at the ring stage, then it
is worthwhile to cryopreserve it after leukocyte depletion of the P.
vivax IRBCs for later use either in the ﬁeld laboratory or in a labo-
ratory located away from the endemic country. Cryopreservation is
necessary for some advanced techniques such as single cell sorting
and some biomechanical studies that necessitate the use of large,
expensive and fragile equipment unsuited to ﬁeld conditions.
When carefully preserved using glycerolyte, P. vivax isolates can
be stored in liquid nitrogen for over a decade with little loss of via-
bility (Rossan, 1985). If the parasitaemia is relatively low, and more
than 1 ml of packed cells is available from the blood sample, it is
highly recommended to use 76% Percoll to concentrate the ring
stages present. This step increases the parasitaemia by 10-fold
(thus allowing experimentation on isolates that would have been
otherwise discarded), and it greatly reduces the volume (2 ml of
packed IRBCs concentrated to <200 ll), which eases the pressures
on the storage space needed and the time needed to thaw. The
use of cryopreserved P. vivax isolates has already opened up a great
number of opportunities for any laboratory, including those with
reduced resources and based in endemic countries, to study P. vi-
vax ex vivo (Borlon et al., 2012).3. Antimalarial drug sensitivity assays
Of all of the ex vivo studies conducted with P. vivax blood sam-
ples, antimalarial drug sensitivity assays are the most commonly
published and have the most practical utility. Ex vivo antimalarial
drug sensitivity testing involves the phenotypic comparison of
freshly isolated or thawed P. vivax, cultured to a speciﬁed endpoint
(schizont stage) in the presence and absence of antimalarial drugs.
These assays provide data on the intrinsic sensitivity of P. vivax to
one or more of these antimalarial drugs. The results are unaffected
by the individuals’ variations in the degree of acquired immunity
when the leukocytes are depleted prior to conducting the assay.
Perhaps the most valuable characteristic of ex vivo studies is that
a large number of standard and novel antimalarial drugs can be
tested simultaneously against target populations of P. vivax. The
ﬁrst ex vivo sensitivity assays on P. vivax were conducted by Müh-
lens and Kirchbaum in 1924 (Field, 1938), the ﬁrst macrotests in
1972 (Powell and Berglund, 1974), followed by the ﬁrst P. vivax
microtest sensitivity assays in 1989 (Renapurkar et al., 1989).
However, it is only since 1994 that these modiﬁed schizont matu-
ration assays have been commonly used for a variety of applica-
tions including: (i) monitoring temporal and spatial changes to
the intrinsic sensitivity of P. vivax to standard antimalarial drugs
(Basco and Le Bras, 1994; Basco et al., 1995; Tan-ariya et al.,
1995; Congpuong et al., 2002; Hamedi et al., 2002, 2003; Tasanor
et al., 2002, 2006; Lux et al., 2003; Russell et al., 2003; Chotivanich
et al., 2004; Kosaisavee et al., 2006; Druilhe et al., 2007; Hasugian
et al., 2009; Phyo et al., 2011; Rijken et al., 2011), (ii) screening new
therapeutic drugs (Lek-Uthai et al., 2008; Leimanis et al., 2010;
Rottmann et al., 2010; Imwong et al., 2011; Marfurt et al., 2011),
(iii) examining inter-species diversity and stage-speciﬁc effects of
antimalarial drugs (Russell et al., 2008; Sharrock et al., 2008),
and (iv) identifying molecular markers of reduced drug sensitivity
(Auliff et al., 2006; Suwanarusk et al., 2007, 2008; Lek-Uthai et al.,
2008; Rijken et al., 2011).
Despite the increasing popularity and general success of such
assays (especially in screening novel compounds), it is important
to understand that the most commonly used method for P. vivax
sensitivity testing, a modiﬁed form of the World Health Organisa-
tion (WHO) schizont maturation assay (Rieckmann et al., 1978),
has a number of important limitations that must be considered.
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limited to schizont maturation, as reinvasion and continued
growth do not occur unless special conditions are met. Therefore,
even with optimal samples where early ring stages predominate,
the upper limit of P. vivax antimalarial drug exposure is in the
range of 42–46 h, making it very difﬁcult to determine the effects
of the slow acting antimalarial drugs such as antibiotics and 8-
amino quinolines. Thus, P. vivax sensitivity proﬁles to slow acting
therapies such as doxycycline and WR238605 return extremely
high IC50 values (Russell et al., 2003), far beyond clinical relevance,
and with the possibility of non-target effects coming into play at
such high concentrations. Given that many of the P. vivax present
in the isolates collected are already at the mature trophozoite
stage, antimalarial drug exposure during the assay is by necessity
limited to 20 h. One may be forgiven for using such isolates for
assay testing, because it is assumed that many of the antimalarial
drugs (especially the 4-amino-quinolines) speciﬁcally target this
stage where haemozoin polymerisation is maximal. However, it
is now well established that P. vivax trophozoites are intrinsically
resistant to chloroquine (CQ) irrespective of the overall sensitivity
of the parasite strain (Powell and Berglund, 1974; Russell et al.,
2008; Sharrock et al., 2008). Consequently, the second important
limitation and perhaps the most serious, is that isolates with less
than 80% ring stages are not suitable for drug susceptibility assays.
Studies using isolates with more than 20% late stage isolates will
invariably provide artiﬁcially high IC50 values, suggesting drug
resistance irrespective of the real sensitivity proﬁle of the P. vivax
population being tested. The simplest way to avoid this is to test
only those isolates with a high proportion of early ring stage, how-
ever this strategy will signiﬁcantly limit usable samples, introduc-
ing possible sample bias and prolonging studies in areas of low
transmission.
Even if rejecting certain isolates is unavoidable (i.e. isolates
with >90% trophozoites and parasitemias <1/1,000), a large num-
ber of isolates can be tested if certain steps are included. These
steps include trypsinisation of the leukocyte depleted IRBCs to re-
move rosettes (Russell et al., 2011b; Udomsangpetch et al., 1995),
followed by a 45% Percoll or magnetic puriﬁcation step (to remove
late stage P. vivax), and ﬁnally a 70% Percoll ring enrichment step
(to concentrate the early ring stages). The ﬁnal yield with this
method depends on the initial volume collected and the initial ring
stage parasitaemia. The following is a typical example of the above
protocol: if 2 ml of packed IRBCs (from 5 ml of whole blood) were
to be collected from a patient with 0.2% parasitaemia where 40% of
the parasites are ring stage, the ﬁnal yield post-enrichment would
be 30 ll of IRBCs with a parasitaemia of 5% (98% ring stage).
After the dilution of such a sample to a 1% parasitaemia, the ﬁnal
volume of 150 ll of IRBCs obtained will be more than adequate
to conduct drug sensitivity assays on two drugs (seven dilutions
plus control) in duplicate. While this method may seem onerous
at the outset, we now regularly apply this approach for particularly
valuable samples (for e.g. those collected from patients with severe
vivax malaria or from suspected recrudescences), or from those
collected in a region of very low transmission. The ﬁnal major fac-
tor limiting the current sensitivity assay is that it relies on the
microscopic assessment of the schizont maturation. While this
method is relatively accurate in the hands of an experienced
microscopist, the inter-reader variability can often be signiﬁcant,
thus careful training and quality assurance are essential. Further-
more, microscopy is rather laborious and time consuming, often
becoming a much-maligned chore of the laboratory staff. Addition-
ally, thick ﬁlms require the use of 4 ll of packed RBCs per well,
which limits the number of assays. Until recently there was no use-
ful alternative to microscopic determination of P. vivax sensitivity,
especially since the radioactive hypoxanthine incorporation and
ﬂuorescent DNA intercalating dye assays that are useful for P. fal-ciparum assays are less successful when applied to P. vivax
(Kosaisavee et al., 2006). The development of ﬂow cytometry
methods to enumerate and characterise parasites and a ﬁeld
deployable ﬂow cytometer now provides a viable and practical
alternative to microscopy (Malleret et al., 2011).
Aside from these speciﬁc problems with the P. vivax schizont
maturation assay, there are a number of other important general
issues with sensitivity assays, irrespective of the species being
tested, such as ensuring the use of folate-reduced media when
testing antifolate drugs (Imwong et al., 2011), and mastering the
mathematical challenges of using serial dilutions (i.e. S.D.s are al-
ways larger for parasite sensitivities of a larger IC50 compared with
those with a lower IC50).4. ‘‘Omics’’
Today it is possible to conduct the full gamut of ‘omic’ studies
(genomic, transcriptomic, metabolomic, etc.) on ex vivo matured
P. vivax (Bozdech et al., 2008). Recent advances in high throughput
sequencing, microarrays, ﬂow cytometry cell sorting and mass
spectrometry now allow a sensitivity that no longer requires the
large target quantities (i.e. parasite, DNA, mRNA, metabolites, pro-
teins or lipids) that were once only possible from the in vivo
expansion of P. vivax in primates (Carlton et al., 2008). One of the
most important challenges facing the accurate ‘‘omic’’ character-
isation of P. vivax isolates is the swamping of the relatively low
parasite signal (mostly due to low parasitaemia) by that of the con-
taminating host leukocytes, platelets and in some cases normo-
blasts. While one round of cellulose ﬁltration is generally
sufﬁcient for drug sensitivity assays, it is not sufﬁcient for ‘‘omic’’
studies where even small quantities of leukocytes (especially lym-
phocytes) can cause signiﬁcant speciﬁc signal loss. To remedy this
problem, it is advisable to pass the sample through at least two
rounds of cellulose ﬁltration, or a post-cellulose Plasmodipur ﬁlter
(Sriprawat et al., 2009). These commercial ﬁlters are less efﬁcient
than cellulose power in removing neutrophils but very efﬁcient
in removing lymphocytes (Sriprawat et al., 2009). In the case of
genomic studies, the ratio of parasite to host DNA can be greatly
improved by ex vivo maturation of the P. vivax to schizont stage,
as this not only increases the amount of parasite DNA (10-fold)
but also removes any residual contaminating leukocytes through
their strong adhesion to the plastic of the culture ﬂask. Should a
particularly pure sample be required, it is advisable to use micro-
beads coated with anti-CD45 antibody (Miltenyi Biotec) and mag-
netic depletion of the leukocytes prior to culture (not after!),
followed after culture by concentrating the schizonts on 45% Per-
coll (Carvalho et al., 2010; Russell et al., 2011b).
Unlike many other microorganisms, malaria parasites undergo
staged development, each involving signiﬁcant changes to the biol-
ogy of the parasite. Therefore, any biologically relevant ‘‘omic’’
study (with the exception of genomics) requires the staged matu-
ration of synchronous early ring-stage isolates (see the section
above for methods to synchronise P. vivax isolates). This involves
splitting the ring-stage isolate into separate ﬂasks and harvesting
these at speciﬁc time points (usually at 6 h (young ring), 12 h (late
ring), 24 h (trophozoite) and 44 h (schizont)). It is important that
these isolates are rapidly frozen in liquid nitrogen or added to pre-
servative (e.g. TRIzol for mRNA preservation) at harvest. Using
this staged ex vivo culture methodology, the P. vivax transcriptome
was ﬁrst described using isolates from Thailand (Bozdech et al.,
2008). It is hoped that future studies will examine the transcrip-
tome (and other ‘omics’) from isolates with a particular phenotype
(i.e. reduced sensitivity to CQ or those causing severe illness) or
from other geographical locations (Westenberger et al., 2010).
The use of concentrated ex vivo isolates for western blot and IFA
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studies.5. Invasion assays
Perhaps the most exciting use for ex vivo studies is in the study
of reticulocyte invasion by the P. vivax merozoite (Table 1).
Although the primary application of such an invasion assay is to
evaluate the ability of vaccine or therapeutic (e.g. small molecules)
formulations to block merozoite invasion, there are many other
important applications relating to the basic biology of P. vivax, such
as the discovery of P. vivax RBC invasion co-receptors (other than
the Duffy antigen). There are two important obstacles facing the
development of robust P. vivax invasion assays. The ﬁrst is the ba-
sic nature of P. vivax isolates that are generally low in parasitaemia
(on average 0.1%), mixed in the stage of development and fragile.
The second is that P. vivax merozoites have a strict preference for
reticulocytes, which are low in number and rapidly develop into
mature erythrocytes that are refractory to invasion by this species.
Therefore, if one were to attempt an invasion assay by simply
maturing an unprocessed P. vivax isolate (a method used effec-
tively in the past for P. falciparum) and then measuring the post-
invasion parasitaemia relative to speciﬁc treatment, one would
ﬁnd that the low post-invasion signal (due to the very small start-
ing parasitaemia and lack of target cells) would be almost impos-
sible to detect above the background noise of dead rings and
trophozoites (which are indistinguishable from true newly infected
RBCs). For this reason none of the published short-term culture
protocols have been applied to assess invasion inhibition. In fact,
the authors of one such protocol clearly stated in the discussion:
‘‘Moreover, quantiﬁcation of the parasite viability was not possible
on the Giemsa stained thick blood ﬁlms. Consequently, the number
of parasitised cells in the next cycle could not be estimated. . .’’
(Udomsangpetch et al., 2007). In the 1980s, four papers proposed
methods to deal with such problems by mixing a concentrated
inoculum consisting of ex vivo matured P. vivax schizonts with
concentrated target cells (reticulocytes) from adult blood, or in
one case cord blood (which provides signiﬁcantly higher yields of
reticulocytes than adult peripheral blood) (Nichols et al., 1987;
Mons et al., 1988a,b; Barnwell et al., 1989). The invasion rates of
these assays were useful and in 1989, Barnwell et al. provided data
to conﬁrm earlier observations that the human Duffy antigen was
an obligate receptor for P. vivaxmerozoite invasion (Barnwell et al.,
1989). Despite the utility of these assays, and the evident need for a
suitable invasion assay for P. vivax, no one has employed these as-
says since 1989. It should be noted that 2007 (Grimberg et al.,
2007) was the ﬁrst time that a P. vivax invasion assay was em-
ployed since 1989, and used basic unprocessed maturation of P. vi-
vax isolates, which resulted in very low post-invasion rates of
0.05%. In an effort to remedy this situation, we developed a P. vi-
vax invasion assay, borrowing heavily from the best parts of each of
the strategies developed in the 1980s, and modifying those for efﬁ-
cient use in a ﬁeld setting (i.e. improved schizont culture media,
Percoll concentration methods and a trypsinisation step to increase
yield) (Russell et al., 2011b). Borlon et al. (2012) further enhanced
the utility of this method by demonstrating that the cryopreserved
cord blood reticulocytes and P. vivax isolates could be used efﬁ-
ciently after transport to locations away from the endemic area.
Ex vivo invasion assay methods are currently being used by a num-
ber of groups to investigate vaccine candidates such as the (P. vivax
Duffy binding protein (PvDBP) (Barnwell et al., 1989; Fang et al.,
1991; Chitnis and Sharma, 2008; Russell et al., 2011b), the P. vivax
merozoite surface proteins 1 and 3 (MSP1 and MSP3) (del Portillo
et al., 1991; Galinski et al., 2001; Galinski and Barnwell, 2008;), the
P. vivax reticulocyte binding proteins (RBP 1 and RBP2) (Galinskiet al., 1992; Rayner et al., 2005; Iyer et al., 2007; Kosaisavee
et al., 2012), the P. vivax apical membrane antigen 1 (PvAMA1)
(Kocken et al., 1999; Bouillet et al., 2011), and invasion into mutant
RBCs and identifying novel co-receptors for P. vivax merozoite
invasion.6. Biomechanical and nanostructural studies
The invasion of the P. vivax merozoite into human reticulocytes
results in signiﬁcant changes to the nanostructural and biome-
chanical properties of the infected cell. Perhaps one of the most
striking changes to the RBC is the development of caveolea vesicle
complexes (CVCs) (seen after methanol ﬁxation and staining with
Giemsa as Schüffner’s stippling) directly associated with the host
cell membrane (Aikawa et al., 1975). Except for the seminal work
by Barnwell et al. (1990), little more is known about these struc-
tures and their speciﬁc function. Recent improvements in P. vivax
sample preparation, staged maturation and concentration, coupled
with new generation nano-imaging devices and markers (such as
coupling Atomic Force Microscopy with functionalised quantum
dots to investigate unﬁxed P. vivax IRBC membrane surfaces) show
a great deal of promise for future studies on the structure and func-
tion of CVCs in human isolates of P. vivax (Russell et al., 2011a).
Modiﬁcations to the P. vivax IRBC membranes result in two bio-
logically signiﬁcant mechanical phenomena, increased deformabi-
lity and adhesiveness (Suwanarusk et al., 2004; Carvalho et al.,
2010). Both of these characteristics were discovered and character-
ised through the careful use of ex vivo matured specimens and
importantly, the actual experiments were carried out in a ﬁeld lab-
oratory or in the endemic country of origin.
When live P. vivax IRBCs are observed in ﬂuid, the size of the
IRBC is of similar size to other uninfected RBCs, whereas it has long
been noted that when smeared on a slide the P. vivax IRBCs have a
signiﬁcantly larger surface area than uninfected RBCs. It was
hypothesised that P. vivax modiﬁes the cell to make it more
deformable, causing it to stretch out as it is smeared. Through
the use of an elegant ﬂow chamber, Suwanarusk et al. (2004) con-
ﬁrmed that P. vivax IRBCs have a signiﬁcantly decreased shear
modulus relative to both P. falciparum IRBCs and uninfected RBCs.
It was then hypothesised that this increased deformability would
allow P. vivax IRBCs to pass through the sinusoids of the spleen’s
red pulp, thus allowing it to avoid splenic clearance. This splenic
survival strategy hypothesis was strongly supported by data col-
lected from a newly developed microﬂuidics system that modelled
the 2 lm splenic sinusoids (Handayani et al., 2009). This system
was deployed to a clinic in West Papua Indonesia, the ﬁrst time
microﬂuidics have been used in a developing country, and this no-
vel method was used to study ﬁeld isolates of P. falciparum and P.
vivax. It should be noted that both of the above strategies would
have greatly beneﬁted from the Percoll concentration methods
mentioned previously; however, as both of these methods involved
single cell observations, as opposed to population measurements
(i.e. rheoscopes), there was no confounding distortion of the rheo-
logical observations due to the background of uninfected RBCs.
While it is possible to employ advanced rheoscopes such as the la-
ser-assisted optical rotational cell analyser (LORCA) to a ﬁeld clinic,
it is vital to enrich the IRBCs to parasitemias greater than 20% to
allow the accurate measurement of the IRBC portion (Safeukui
et al., 2008). New techniques using a sorting device containing
microbeads (Deplaine et al., 2011) which mimic the narrow and
short splenic capillary should be tested with P. vivax IRBCs to com-
pare with existing methods.
While P. vivax does not sequester in the same manner as P. fal-
ciparum, it has long been noted that the mature IRBCs of this spe-
cies have a tendency to withdraw from the peripheral circulation,
Table 1
Review of past Plasmodium vivax (Pv) invasion assays.
Study Basic method Parasite sample diversity Maturation media Host blood cells
used
Invaded cells
in ‘x’ RBCs
Mean new invasion
parasitemia
Comments
1. Nichols et al.
(1987)
Concentration of ex vivo
matured Pv (54% Percoll) on
host cells (65% Percoll)
mixed 1:5 or 1:10
One primate adapted strain
Pv (Belem)
RPMI 1640 with, HEPES,
hypoxanthine, D-glucose, 10%
AB+ serum
Human (adult
peripheral), ape
and monkey
2,000 Not provided, just ± Limited details on method and no
data given on the actual parasitemia
of the invasion
2. Mons et al.
(1988b)
Concentration of ex vivo
matured Pv (58% Nycodenz)
on host cells (60%
Nycodenz) mixed 1:5 or
1:10
Eight human isolates RPMI 1640 with
hypoxanthine, HEPES,
NaHCO3, neomycine, MgCl2,
ascorbic acid, choline, biotin,
vitamin B-12, 15% AB+ serum
Human cord;
bone marrow;
peripheral
10,000 0.93% (range 0.2–2.5) at
10 h
Apart from our study this is the only
that has used more than two human
isolates for an invasion assay.
Unfortunately the concentration of Pv
(35–50%) and reticulocytes was
(5–30%). The lack of purity in the
stages of the invasion mix brings into
question the absolute speciﬁcity of
this study
3. Mons et al.
(1988a)
Concentration of ex vivo
matured Pv (58% Nycodenz)
on in vivo enriched host
cells 1:1
One primate adapted strain
Pv (Palo Alto)
RPM1 1640 with HEPES,
NaHCO3, neomycine, 20% AB+
serum
Monkey
peripheral post
phenylhydrazine
HCl treatment
10,000
(microscopy)
100,000
(Cytometry)
11.9% (SD ±8.7%) at 15 h Good invasion rates. However, not
applicable to ﬁeld work
4. Barnwell et al.
(1989)
Concentration of ex vivo
matured Pv (54% Percoll) on
host cells (65% Percoll)
mixed 1:5 or 1:10
One primate adapted strain
Pv (Belem)
RPMI 1640 with HEPES,
hypoxanthine, D-glucose, 10%
AB+ serum
Human (adult
peripheral) and
monkey
2,000 8.3% (range 3–14%) Many experiments carried out using
one primate adapted P. vivax strain.
Effective methodology, but not
proven using human isolates. No
details on yield(volume) of
concentrated parasites or
reticulocytes
5. Grimberg et al.
(2007)
Asynchronous late-stage P.
vivax cultured and grown
for 24 h. No new or enriched
host cells added
Two human isolates McCoy’s 5A medium with
HEPES, NaHCO3, glutamine,
gentamicin, 25% AB+ serum
Human
peripheral
20,000 Total 0.1% (range 0.103–
0.105%) at 24 h. However
only 0.05% if considering
new ‘invasions’
This ‘assay’ did not use the earlier and
more sophisticated methods of
Barnwell or Mons. As the isolates
were not used soon after the isolation
(>12 h), there is a high chance of
parasite death. Thus a signiﬁcant
proportion of rings and trophozoites
could be moribund, rather than
supposed new invasions
6. Russell et al.
(2011a,b)
Concentration of ex vivo
matured Trypsin treated Pv
(45% Percoll) on host cells
(70% Percoll) mixed 1:6
85 human isolates McCoy’s 5A medium with
glutamine, gentamicin,
glucose, 20% AB+ serum
Human cord 4,000 3.7% (range 0.1–22.3%) at
24 h
Adapted from Mons and Barnwell,
this method has been successfully
applied to cryopreserved isolates of
Pv by Borlon et al. (2012)
RBC, red blood cell.
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stick to uninfected RBCs to form the characteristic rosette
structures ﬁrst observed in P. falciparum. However, it was not until
Carvalho et al. (2010) conducted a range of ex vivo experiments, in
a ﬁeld laboratory in the Brazilian Amazon, that the speciﬁc cytoad-
hesive characteristics of P. vivax IRBCs were ﬁrst properly charac-
terised. Interestingly, this study took advantage of a number of
ex vivo methodologies (i.e. leukocyte removal, staged maturation
and Percoll enrichment) to aid in the observation. A subsequent
study has used ex vivo isolates to investigate the increased
cytoadhesion in Thai isolates to placental glycosaminoglycans
(Chotivanich et al., 2012). Although the role of P. vivax cytoadhe-
siveness in the pathology of vivax malaria is yet to be determined,
it is anticipated that ongoing ex vivo characterisation of P. vivax
isolates obtained from patients with well deﬁned clinical
phenotypes might provide such answers.7. Conclusions
Although each of the above methodologies has been examined
individually, it cannot be stressed enough that more than one of
these applications can be conducted on the same isolate. For exam-
ple the collection of a 10 ml isolate of P. vivaxwith a parasitemia of
0.4% (with >80% at the ring stage) would enable the complete char-
acterisation of this isolate with every application mentioned
(including one genome and one other staged ‘omic’ study, such
as the transcriptome). Data from such a multifaceted study would
be force multiplied if the isolate was obtained from a patient with a
complete and longitudinal clinical proﬁle. An example of such a
multidisciplinary work was conducted by Rijken et al. (2011),
and was the ﬁrst known study to compare ex vivo, in vivo and
molecular correlates of P. vivax drug resistance.
We hope that this discussion enthuses current and would-be vi-
vax researchers with the real possibilities of studying P. vivax. Far
from being a stopgap while we wait for P. vivax continuous
in vitro cultivation to arrive, ex vivo studies on P. vivax can and will
provide answers to important practical questions facing those en-
gaged in the diagnosis, treatment and control of vivax malaria.
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